

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect



## Journal of the Neurological Sciences

journal homepage: www.elsevier.com/locate/jns



# Peripheral neurological complications during COVID-19: A single center experience

Nara Miriam Michaelson<sup>a,\*</sup>, Ashwin Malhotra<sup>a</sup>, Zehui Wang<sup>a</sup>, Linda Heier<sup>b</sup>, Kurenai Tanji<sup>c</sup>, Scott Wolfe<sup>d</sup>, Alka Gupta<sup>e</sup>, Daniel MacGowan<sup>a</sup>

<sup>a</sup> New York-Presbyterian Hospital/Weill Cornell Medical Center, Department of Neurology, New York, NY, United States of America

<sup>b</sup> NewYork-Presbyterian Hospital/Weill Cornell Medical Center, Department of Radiology, New York, NY, United States of America

<sup>c</sup> NewYork-Presbyterian Hospital/Columbia University Medical Center, Departments of Neurology, Pathology, and Cell Biology, New York, NY, United States of America

<sup>d</sup> Hospital for Special Surgery, Weill Cornell Medical College, Department of Orthopedic Surgery, New York, NY, United States of America

<sup>e</sup> NewYork-Presbyterian Hospital/Weill Cornell Medical Center, Department of Medicine, New York, NY, United States of America

#### ARTICLE INFO

Keywords: COVID-19 SARS-CoV-2 Brachial plexopathy Peripheral neuropathy Entrapment neuropathy RA02

#### ABSTRACT

*Background and aims*: We highlight the peripheral neurologic complications of coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an ongoing global health emergency.

*Methods*: We evaluated twenty-five patients admitted to the COVID-19 Recovery Unit (CRU) at New York-Presbyterian Weill Cornell University Medical Center after intensive care hospitalization with confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), whom neurology was consulted for weakness and/ or paresthesias. All patients were clinically evaluated by a neuromuscular neurologist who performed electrodiagnostic (EDX) studies when indicated. Magnetic resonance imaging (MRI) of the affected regions, along with nerve and muscle biopsies were obtained in select patients to better elucidate the underlying diagnosis. *Results*: We found fourteen out of twenty-five patients with prolonged hospitalization for COVID-19 infection to have peripheral neurological complications, identified as plexopathies, peripheral neuropathies and entrapment neuropathies. The other eleven patients were not found to have peripheral neuropathies for their symptoms. Patients with perioheral neurological complications often exhibited more than one type of concurrently. Spe-

cifically, there were four cases of plexopathies, nine cases of entrapment neuropathies, and six cases of peripheral neuropathies, which included cranial neuropathy, sciatic neuropathy, and multiple mononeuropathies. *Conclusions:* We explore the possibility that the idiopathic peripheral neurologic complications could be manifestations of the COVID-19 disease spectrum, possibly resulting from micro-thrombotic induced nerve ischemia.

#### 1. Introduction

Many neurological complications of the coronavirus disease 2019 (COVID-19) pandemic, such as encephalitis, ischemic stroke, and acute inflammatory demyelinating polyneuropathy (AIDP) have been documented in the literature [1,2]. However, the full spectrum of peripheral neurological complications of COVID-19 and risk factors have not been well described. Here we present a single center experience as a case series of peripheral neurological complications observed in patients hospitalized with COVID-19.

#### 2. Materials and methods

From March to June of two thousand twenty-one, the neurology service evaluated twenty-five patients admitted to the COVID-19 Recovery Unit (CRU) at New York-Presbyterian Weill Cornell University Medical Center after intensive care hospitalization with confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), whom neurology was consulted for weakness and/or paresthesias. All patients were clinically evaluated by a neuromuscular neurologist who performed electrodiagnostic (EDX) studies when indicated. Magnetic resonance imaging (MRI) of the affected regions, along with nerve and

https://doi.org/10.1016/j.jns.2021.120118

Received 19 September 2021; Received in revised form 27 November 2021; Accepted 19 December 2021 Available online 23 December 2021 0022-510X/© 2021 Elsevier B.V. All rights reserved.

<sup>\*</sup> Corresponding author at: Peripheral Neuropathy Center, New York-Presbyterian Hospital/Weill Cornell Medicine, 1305 York Avenue, 2nd Floor, New York, NY 10021, United States of America.

E-mail address: nam9193@nyp.org (N.M. Michaelson).

#### N.M. Michaelson et al.

muscle biopsies were obtained in select patients to better elucidate the underlying diagnosis.

#### 3. Results

Table 1 describes key demographic patient data, comorbidities, inpatient complications, and relevant peak lab values organized by type of peripheral neurological complication. Table 2 summarizes results EDX studies, MRIs, and muscle and nerve biopsies by peripheral neurologic complication diagnosis. There were ultimately fourteen patients that were found to have peripheral neurological complications from the original twenty-five patients we were asked to evaluate (the remaining eleven were not found to have peripheral causes for their symptoms).

Of the four patients with sciatic neuropathies, one with bilateral sciatic neuropathies was explained by rhabdomyolysis induced bilateral

#### Table 1

Demographics, characteristics, and peripheral neurological complication

Plexopathy (n = 4)Peripheral neuropathy (n = 6)Entrapment neuropathy (n = 10)Median age, range (years)57, 33-8254, 43-6651, 33-7156, 33-82Male no. (%)144 (100)6 (100)9 (100)(100)(100)(100)(100)White no. (%)6 (43)1 (25)4 (67)3 (33)Hispanic/Latino no. (%)2 (14)0 (0)0 (0)2 (22)COVID-19 status no. (%)134 (100)5 (83)9 (100)(%)(93)(125)1 (17)6 (67)(%)(100)(100)(100)9 (100)Paralysis during6 (43)2 (50)4 (67)3 (33)(%)(100)(100)(100)(100)Pronation for ARDS no.4 (29)2 (50)2 (33)3 (33)(%)(17)1 (25)1 (17)1 (11)(%)(93)(20)0 (0)3 (50)2 (22)Rhabdomyolysis no. (%)1 (7)1 (25)1 (17)1 (11)Vasopressor support no.114 (100)5 (83)3 (33)(%)(79)2 (50)2 (33)3 (33)RRT no. (%)7 (50)3 (75)3 (50)5 (56)COVID-19 diagnosis to anset (days)2 (53)5 35 348hospitalization (days)22 82423(%)(79)25 35 348hospitalization (%)7 (50)3 (75)3 (50)5 (56)<	Total patients (14)		Peripheral neurological complication		
(years) $33-82$ Male no. (%)  14  4 (100)  6 (100)  9 (100)    (100)  (100)  (100)  (100)  (210)    White no. (%)  6 (43)  1 (25)  4 (67)  3 (33)    Hispanic/Latino no. (%)  6 (43)  3 (75)  2 (33)  4 (44)    Asian no. (%)  2 (14)  0 (0)  0 (0)  2 (22)    COVID-19 status no. (%)  13  4 (100)  5 (83)  9 (100)    (93)  (93)  (17)  4 (44)    Diabetes mellitus no.  6 (43)  1 (25)  1 (17)  4 (44)    Intubation for COVID-19  14  4 (100)  6 (100)  9 (100)    no. (%)  (100)  (100)  9 (100)  (33)    (%)  (100)  6 (100)  8 (89)  (%)    Pronation for ARDS no.  4 (29)  2 (50)  2 (33)  3 (33)    (%)  (93)  (643)  1 (25)  4 (67)  3 (33)    (%)  (93)  (71  1 (25)  1 (17)  1 (11)    Cuticosteroids use no.  6 (43) <t< th=""><th></th><th></th><th></th><th>neuropathy</th><th>neuropathy</th></t<>				neuropathy	neuropathy
Male no. (%)  14  4 (100)  6 (100)  9 (100)    (100)  (100)  (100)  (100)  (100)    White no. (%)  6 (43)  1 (25)  4 (67)  3 (33)    Hispanic/Latino no. (%)  6 (43)  3 (75)  2 (33)  4 (44)    Asian no. (%)  2 (14)  0 (0)  0 (0)  2 (22)    COVID-19 status no. (%)  13  4 (100)  5 (83)  9 (100)    (%)  (%)  1 (25)  1 (17)  4 (44)    Intubation for COVID-19  14  4 (100)  6 (100)  9 (100)    no. (%)  (100)			54, 43–66	51, 33–71	56, 33–82
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	•		4 (100)	6 (100)	0 (100)
White no. (%)  6 (43)  1 (25)  4 (67)  3 (33)    Hispanic/Latino no. (%)  2 (14)  0 (0)  0 (0)  2 (22)    COVID-19 status no. (%)  13  4 (100)  5 (83)  9 (100)    (93)	Male no. (%)		4 (100)	6 (100)	9 (100)
Hispanic/Latino no. (%)6 (43)3 (75)2 (33)4 (44)Asian no. (%)2 (14)0 (0)0 (0)2 (22)COVID-19 status no. (%)134 (100)5 (83)9 (100)(93)(93)(125)1 (17)6 (67)(%)4 (29)1 (25)1 (17)4 (44)Intubation for COVID-19144 (100)6 (100)9 (100)no. (%)(100)(100)Paralysis during6 (43)2 (50)4 (67)3 (33)hospitalization no.(%)(100)8 (89)(%)(%)8 (89)(%)(93)(100)6 (100)8 (89)(%)(93)Corticosteroids use no.6 (43)1 (25)4 (67)3 (33)(%)(93)(100)3 (50)2 (22)Remedesivir no. (%)4 (29)0 (0)3 (50)2 (22)Rhabdomyolysis no. (%)1 (7)1 (25)1 (17)1 (11)Cutaneous rash no. (%)2 (14)1 (25)1 (17)1 (11)VTE no. (%)5 (36)2 (50)2 (33)3 (33)Vasopressor support no.114 (100)5 (83)7 (78)(%)(79)(750)3 (75)3 (50)5 (56)COVID-19 diagnosis to35373335neurological(days)22282423(days)2222222Length of52535348hospitalization (days) <td< td=""><td>White po (04)</td><td></td><td>1 (25)</td><td>4 (67)</td><td>2 (22)</td></td<>	White po (04)		1 (25)	4 (67)	2 (22)
Asian no. (%)2 (14)0 (0)0 (0)2 (22)COVID-19 status no. (%)134 (100)5 (83)9 (100)(%)(93)(25)1 (17)6 (67)(%)(%)1 (25)1 (17)4 (44)Intubation for COVID-19144 (100)6 (100)9 (100)no. (%)(100)(100)(%)9 (100)(%)Paralysis during6 (43)2 (50)4 (67)3 (33)nospitalization no.(%)(93)(%)(%)Pronation for ARDS no.4 (29)2 (50)2 (33)3 (33)(%)(%)(93)(%)(%)(7)3 (50)Corticosteroids use no.6 (43)1 (25)4 (67)3 (33)(%)(%)(17)1 (125)1 (17)1 (11)Cutaneous rash no. (%)2 (14)1 (25)1 (17)1 (11)VTE no. (%)5 (36)2 (50)2 (33)3 (33)Vasopressor support no.114 (100)5 (83)7 (78)(%)(79)(750)3 (75)3 (50)5 (56)COVID-19 diagnosis to35373335neurologicalsymptoms onset22282423(days)222282423Length of52535348hospitalization (days)22282423Length of rehabilitation2228251724612710D-dimer (mg/mL) <td></td> <td></td> <td></td> <td></td> <td></td>					
$\begin{array}{c} {\rm COVID-19 \ status no. (\%)} & 13 & 4 (100) & 5 (83) & 9 (100) \\ & (93) & & & \\ {\rm Diabetes \ mellitus \ no.} & 6 (43) & 1 (25) & 1 (17) & 6 (67) \\ (\%) & & & \\ {\rm Obesity \ no. (\%)} & 4 (29) & 1 (25) & 1 (17) & 4 (44) \\ {\rm Intubation \ for \ COVID-19} & 14 & 4 (100) & 6 (100) & 9 (100) \\ {\rm no. (\%)} & & & & \\ {\rm Paralysis \ during} & 6 (43) & 2 (50) & 4 (67) & 3 (33) \\ {\rm hospitalization \ no.} & (\%) & & \\ {\rm (\%)} & & & & \\ {\rm Fronation \ for \ ARDS \ no.} & 4 (29) & 2 (50) & 2 (33) & 3 (33) \\ (\%) & & & \\ {\rm Hydroxychloroquine \ no.} & 13 & 4 (100) & 6 (100) & 8 (89) \\ (\%) & & & & \\ {\rm (\%)} & & & & \\ {\rm Corticosteroids \ use \ no.} & 6 (43) & 1 (25) & 4 (67) & 3 (33) \\ (\%) & & & \\ {\rm Remedesivir \ no.} (\%) & 4 (29) & 0 (0) & 3 (50) & 2 (22) \\ {\rm Rhabdomyolysis \ no.} (\%) & 1 (7) & 1 (25) & 1 (17) & 1 (11) \\ {\rm Cutaneous \ rash \ no.} (\%) & 2 (14) & 1 (25) & 1 (17) & 1 (11) \\ {\rm Cutaneous \ rash \ no.} (\%) & 5 (36) & 2 (50) & 2 (33) & 3 (33) \\ {\rm Nasopressor \ support \ no.} & 11 & 4 (100) & 5 (83) & 7 (78) \\ (\%) & & & \\ {\rm (\%)} & & & \\ {\rm (\%)} & & & \\ {\rm Length \ of \ columnation \ solved \ (days)} \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 24 & 23 \\ {\rm (days)} & \\ {\rm Length \ of \ rehabilitation \ 22 & 28 & 2517 & 2461 & 2710 \\ {\rm D-dimer \ (ng/mL)} & 4916 & 4820 & 6427 & 3255 \\ {\rm CPP \ (mg/dL)} & 128 & 93 & 126 & 119 \\ \end{array}}$	-				
(93)    (17)    (6)      Diabetes mellitus no.    6 (43)    1 (25)    1 (17)    6 (67)      (%6)    (100)    1 (25)    1 (17)    4 (44)      Intubation for COVID-19    14    4 (100)    6 (100)    9 (100)      Paralysis during    6 (43)    2 (50)    4 (67)    3 (33)      hospitalization no.    (%6)    93)    (%6)    (93)      Corticosteroids use no.    6 (43)    1 (25)    4 (67)    3 (33)      (%6)    (93)    (%6)    (%3)    2 (20)    2 (33)    3 (33)      (%6)    (93)    (%6)    (%3)    2 (22)    Rhabdomyolysis no. (%6)    1 (7)    1 (25)    1 (17)    1 (11)      Corticosteroids use no.    6 (43)    1 (25)    1 (17)    1 (11)      Cutaneous rash no. (%6)    2 (14)    1 (25)    1 (17)    1 (11)      VTE no. (%6)    5 (36)    2 (50)    2 (33)    3 (33)      Vasopressor support no.    11    4 (100)    5 (83)    7 (78)					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	COVID-19 status IIO. (%)		4 (100)	5 (65)	9 (100)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Diabetes mellitus no	• •	1 (25)	1 (17)	6 (67)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0 (43)	1 (23)	1(17)	0(07)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	• •	4 (29)	1 (25)	1 (17)	4 (44)
no. (%)(100)Paralysis during $6$ (43) $2$ (50) $4$ (67) $3$ (33)hospitalization no.(%) $2$ (50) $2$ (33) $3$ (33)(%)Pronation for ARDS no. $4$ (29) $2$ (50) $2$ (33) $3$ (33)(%)(%)(93) $6$ $6$ $100$ $8$ (89)(%)(93) $6$ $6$ $100$ $8$ (89)(%)(93) $6$ $6$ $100$ $8$ (89)(%)(93) $6$ $100$ $8$ (89)(%)(93) $6$ $100$ $8$ (89)(%)(93) $6$ $100$ $8$ (89)(%)(93) $6$ $100$ $8$ (89)(%)(93) $1$ $125$ $4$ (67) $3$ (33)(%) $7$ $1$ $125$ $1$ $17$ $1$ Cutaneous rash no. (%) $2$ (14) $1$ $125$ $1$ $177$ $1$ VTE no. (%) $5$ $36$ $2$ $2$ $33$ $3$ $33$ RRT no. (%) $5$ $36$ $2$ $2$ $33$ $3$ $33$ Vasopressor support no. $11$ $4$ $100$ $5$ $83$ $7$ $78$ (%)(%)(79) $750$ $3$ $55$ $53$ $53$ $48$ hospitalization (days) $22$ $28$ $24$ $23$ $23$ Length of rehabilitation $22$ $28$ $24$ $23$ $23$ (days) $2450$ $4820$ $6427$ $3255$ <	, . <i>,</i>		. ,	. ,	
Paralysis during  6 (43)  2 (50)  4 (67)  3 (33)    hospitalization no.  (%)  7  7  3 (33)    Pronation for ARDS no.  4 (29)  2 (50)  2 (33)  3 (33)    (%)  1  2 (50)  2 (33)  3 (33)    (%)  93)  6 (100)  8 (89)    (%)  (93)  7  3 (33)    (%)  (93)  7  3 (33)    (%)  (93)  7  3 (33)    (%)  (93)  7  3 (33)    Corticosteroids use no.  6 (43)  1 (25)  4 (67)  3 (33)    (%)  (93)  7  3 (33)  3  3  3    Remedesivir no. (%)  4 (29)  0 (0)  3 (50)  2 (22)  Rhabdomyolysis no. (%)  1 (7)  1 (15)  1 (17)  1 (11)    Cutaneous rash no. (%)  5 (36)  2 (50)  2 (33)  3 (33)  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3 <td< td=""><td></td><td></td><td>1(100)</td><td>0 (100)</td><td>5 (100)</td></td<>			1(100)	0 (100)	5 (100)
hospitalization no. (%) Pronation for ARDS no. 4 (29) 2 (50) 2 (33) 3 (33) (%) Hydroxychloroquine no. 13 4 (100) 6 (100) 8 (89) (%) Corticosteroids use no. 6 (43) 1 (25) 4 (67) 3 (33) (%) Remedesivir no. (%) Remedesivir no. (%) Remedesivir no. (%) 1 (7) 1 (25) 1 (17) 1 (11) Cutaneous rash no. (%) 1 (7) 1 (25) 1 (17) 1 (11) Cutaneous rash no. (%) 5 (36) 2 (50) 2 (33) 3 (33) RRT no. (%) 5 (36) 2 (50) 2 (33) 3 (33) Vasopressor support no. 11 4 (100) 5 (83) 7 (78) (%) (%) COVID-19 diagnosis to 35 37 33 35 neurological symptoms onset (days) Length of 52 53 53 48 hospitalization (days) Length of 52 2 53 53 48 hospitalization (days) Length of 52 2 53 53 48 hospitalization (days) Length of 2 2 28 2 4 2 3 2 4 2 3 2 5 5 7 2 461 2 710 D-dimer (ng/mL) 4 916 4 820 6 427 3 255 CRP (mg/dL) 1 28 9 3 1 26 1 19		. ,	2 (50)	4 (67)	3 (33)
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	hospitalization no.	- ( ) - )	_ (00)		- ()
(%)  (93)    Corticosteroids use no.  6 (43)  1 (25)  4 (67)  3 (33)    (%)  (%)  1 (25)  4 (67)  3 (33)    Remedesivir no. (%)  4 (29)  0 (0)  3 (50)  2 (22)    Rhabdomyolysis no. (%)  1 (7)  1 (25)  1 (17)  1 (11)    Cutaneous rash no. (%)  2 (14)  1 (25)  1 (17)  1 (11)    VTE no. (%)  5 (36)  2 (50)  2 (33)  3 (33)    RAT no. (%)  5 (36)  2 (50)  2 (33)  3 (33)    Vasopressor support no.  11  4 (100)  5 (83)  7 (78)    (%)  (79)  750  3 (75)  3 (50)  5 (56)    COVID-19 diagnosis to  35  37  33  35    neurological symptoms onset (days)  2  28  24  23    Length of  52  53  53  48    hospitalization (days)  2  28  24  23    Length of rehabilitation  22  28  24  23    (days)  2  28  24 </td <td></td> <td>4 (29)</td> <td>2 (50)</td> <td>2 (33)</td> <td>3 (33)</td>		4 (29)	2 (50)	2 (33)	3 (33)
$\begin{array}{c c} (\%) & & & & & & & & & & & & & & & & & & &$			4 (100)	6 (100)	8 (89)
Rhabdomyolysis no. (%)  1 (7)  1 (25)  1 (17)  1 (11)    Cutaneous rash no. (%)  2 (14)  1 (25)  1 (17)  1 (11)    VTE no. (%)  5 (36)  2 (50)  2 (33)  3 (33)    RRT no. (%)  5 (36)  2 (50)  2 (33)  3 (33)    Vasopressor support no.  11  4 (100)  5 (83)  7 (78)    (%)  (79)  7 (50)  3 (75)  3 (50)  5 (56)    COVID-19 diagnosis to  35  37  33  35    neurological  symptoms onset  (days)  44  44  44    Length of  52  53  53  48  48    hospitalization (days)  22  28  24  23  23    (days)  22  28  24  23  23  24  23  24  23  24  23  24  23  24  23  24  24  23  24  24  24  24  24  24  25  25  25  25  25  25  25  25  25	Corticosteroids use no.		1 (25)	4 (67)	3 (33)
Cutaneous rash no. (%)    2 (14)    1 (25)    1 (17)    1 (11)      VTE no. (%)    5 (36)    2 (50)    2 (33)    3 (33)      RRT no. (%)    5 (36)    2 (50)    2 (33)    3 (33)      Nasopressor support no.    11    4 (100)    5 (83)    7 (78)      (%)    (79)    3    5    33    35      Bacteremia no. (%)    7 (50)    3 (75)    3 (50)    5 (56)      COVID-19 diagnosis to    35    37    33    35      neurological    symptoms onset    (days)    44    46    46      Length of    52    53    53    48    46      hospitalization (days)    12    28    24    23    23      (days)    22    28    24    23    23      Average peak values    1958    2517    2461    2710      D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119	Remedesivir no. (%)	4 (29)	0 (0)	3 (50)	2 (22)
VTE no. (%)    5 (36)    2 (50)    2 (33)    3 (33)      RRT no. (%)    5 (36)    2 (50)    2 (33)    3 (33)      Vasopressor support no.    11    4 (100)    5 (83)    7 (78)      (%)    (79)    7    7    3 (50)    5 (56)      COVID-19 diagnosis to    35    37    3 (50)    5 (56)      COVID-19 diagnosis to    35    37    33    35      neurological    35    37    33    35      symptoms onset    (days)    2    28    24    23      Length of rehabilitation    22    28    24    23      (days)    2    28    24    23      Average peak values    2    28    24    23      CPK (U/L)    1958    2517    2461    2710      D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119	Rhabdomyolysis no. (%)	1 (7)	1 (25)	1 (17)	1 (11)
RRT no. (%)  5 (36)  2 (50)  2 (33)  3 (33)    Vasopressor support no.  11  4 (100)  5 (83)  7 (78)    (%)  (79)  7 (50)  3 (75)  3 (50)  5 (56)    COVID-19 diagnosis to  35  37  33  35    neurological symptoms onset (days)  52  53  53  48    hospitalization (days)  22  28  24  23    Length of rehabilitation (days)  22  28  24  23    Average peak values  CPK (U/L)  1958  2517  2461  2710    D-dimer (ng/mL)  4916  4820  6427  3255  GRP (mg/dL)  128  93  126  119	Cutaneous rash no. (%)	2 (14)	1 (25)	1 (17)	1 (11)
Vasopressor support no.    11    4 (100)    5 (83)    7 (78)      (%)    (79)    (75)    3 (50)    5 (56)      Bacteremia no. (%)    7 (50)    3 (75)    3 (50)    5 (56)      COVID-19 diagnosis to    35    37    33    35      neurological symptoms onset (days)    52    53    53    48      hospitalization (days)    22    28    24    23      (days)    22    28    24    23      (days)    22    28    24    23      CPK (U/L)    1958    2517    2461    2710      D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119	VTE no. (%)	5 (36)	2 (50)	2 (33)	3 (33)
(%)  (79)    Bacteremia no. (%)  7 (50)  3 (75)  3 (50)  5 (56)    COVID-19 diagnosis to  35  37  33  35    neurological symptoms onset (days)  -  -  -  -    Length of  52  53  53  48    hospitalization (days)  -  -  -  -    Length of rehabilitation  22  28  24  23    (days)  -  -  -  -    Average peak values  -  -  -  -    CPK (U/L)  1958  2517  2461  2710    D-dimer (ng/mL)  4916  4820  6427  3255    CRP (mg/dL)  128  93  126  119	RRT no. (%)	5 (36)	2 (50)	2 (33)	3 (33)
Bacteremia no. (%)    7 (50)    3 (75)    3 (50)    5 (56)      COVID-19 diagnosis to    35    37    33    35      neurological symptoms onset (days)    3    55    53    48      Length of    52    53    53    48      hospitalization (days)    2    28    24    23      (days)    22    28    24    23      (days)    22    28    24    23      (days)    22    28    24    23      (days)    21    28    24    23      (days)    255    77    2461    2710      D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119	Vasopressor support no.	11	4 (100)	5 (83)	7 (78)
COVID-19 diagnosis to neurological symptoms onset (days)    35    37    33    35      Length of    52    53    53    48      hospitalization (days)    Length of rehabilitation    22    28    24    23      (days)    Average peak values    2    28    24    23      CPK (U/L)    1958    2517    2461    2710      D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119	(%)	(79)			
neurological symptoms onset (days) Length of 52 53 53 48 hospitalization (days) Length of rehabilitation 22 28 24 23 (days) Average peak values CPK (U/L) 1958 2517 2461 2710 D-dimer (ng/mL) 4916 4820 6427 3255 CRP (mg/dL) 128 93 126 119	Bacteremia no. (%)	7 (50)	3 (75)	3 (50)	5 (56)
Length of    52    53    53    48      hospitalization (days)	neurological symptoms onset	35	37	33	35
Average peak values    22    28    24    23      CPK (U/L)    1958    2517    2461    2710      D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119		52	53	53	48
Length of rehabilitation 22 28 24 23 (days) Average peak values CPK (U/L) 1958 2517 2461 2710 D-dimer (ng/mL) 4916 4820 6427 3255 CRP (mg/dL) 128 93 126 119	•		50	50	10
(days) Average peak values CPK (U/L) 1958 2517 2461 2710 D-dimer (ng/mL) 4916 4820 6427 3255 CRP (mg/dL) 128 93 126 119		22	28	24	23
CPK (U/L)    1958    2517    2461    2710      D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119	0				
D-dimer (ng/mL)    4916    4820    6427    3255      CRP (mg/dL)    128    93    126    119		1050	0575	0.465	0.510
CRP (mg/dL) 128 93 126 119					
				* .=.	
ESIX (IIIII/ II) 100 101 113 100					
Ferritin (ng/mL) 2358 1875 2794 2467					

Abbreviations: n = total cases of neuropathy in each category. ARDS: acute respiratory distress syndrome. VTE: venous thromboembolism. RRT: renal replacement therapy. CPK: creatine phosphokinase. CRP: C-reactive protein. ESR: erythrocyte sedimentation rate.

Table 2

Patient no.	Peripheral neurologic	Electrodiagnostic studies	Muscle & nerve biopsies
	complication		Magnetic resonance imaging
1	Brachial plexopathy	L. brachial plexopathy with sparing of axillary n. and suprascapular n. fibers	Not done L. brachial plexus showed asymmetric T2-hyperintensity of plexus trunks, divisions, and cords
2	Brachial plexopathy	L. brachial plexopathy with sparing of axillary n. fibers	Not done Diffuse L. brachial plexitis with serratus anterior muscle T2- hyperintense signal and enhancement reflecting acute denervation edema
3	Brachial plexopathy	Normal	Not done L. brachial plexus showed increased T2 signal of the left C5 C6 and C7 nerve roo extending to the uppe
	Peripheral neuropathy	Bilateral sciatic neuropathies	and middle trunks L. PB. m biopsy: seven myofiber atrophy, ran myonecrosis L. sural n. biopsy:
4	Brachial plexopathy	Bilateral upper trunk brachial plexopathies	severe, active axona loss Bilateral brachial ple:
	Entrapment neuropathy	Triceps-sparing L. radial neuropathy	showed increased T signal in the C5/C6 roots
		Multiple mononeuropathies: R.	Not done
5	Peripheral neuropathy	radial n., musculocutaneous n., median n.	Normal MRI of the F brachial plexus
	Peripheral neuropathy	Bilateral sciatic neuropathies	R. PB m. biopsy: moderate m. atroph R. medial antebrachi cutaneous n. biopsy myelinated axon los with numerous
6	Entrapment neuropathy	Bilateral cubital tunnel syndromes; R. PIN entrapment	phagocytosing macrophages withir the endoneurium MRI R. forearm showed T2- hyperintense posterio
7	Peripheral neuropathy	L. sciatic neuropathy	interosseous nerve in the Arcade of Frohse Not done MRI L. lumbosacral plexus without contrast showed an enlarged, edematous L. sciatic nerve behin the L. greater trochanter, distal to the sciatic notch R. SPN biopsy: sever axonal neuropathy
8	Peripheral neuropathy	Bilateral sciatic neuropathies	without vasculitis or thrombosis R. PB m. biopsy: extensive m. atrophy MRI not done (norma CT pelvis without contrast)
9	Peripheral neuropathy	Complete R. facial axonotmesis	Not done MRI brain shows lon segment enhancemer

N.M. Michaelson et al.

Table 2 (continued)


Patient no.	Peripheral neurologic	Electrodiagnostic studies	Muscle & nerve biopsies
	complication		Magnetic resonance imaging
			of the R. facial nerve from the fundus of the intra-canalicular segment through the mastoid
		Not done; clinical	Not done
10	10 Entrapment neuropathy	diagnosis of bilateral common peroneal entrapment neuropathies at the fibular heads	Not done
		Bilateral common peroneal	Not done
11	Entrapment neuropathy	(axonotmetic) neuropathies at the fibular head	Not done
		L. common peroneal	Not done
12	Entrapment neuropathies	neuropathy at fibular head; R. median neuropathy at the wrist	Not done
13	Entrapment neuropathy	R. ulnar neuropathy at cubital tunnel	Not done Not done Not done
14	Entrapment neuropathies	R. ulnar neuropathy at Guyon's canal; L. common peroneal neuropathy at the fibular head	MRI R. wrist showed R. ulnar nerve enlargement and increased signal in Guyon's canal


**Abbreviations:** L = left, R = right, PB = peroneus brevis muscle, m. biopsy = muscle biopsy, SPN = superficial peroneal nerve, n. biopsy = nerve biopsy, PIN = posterior interosseous nerve.

gluteal compartment syndromes, with a peak creatine phosphokinase levels of greater than 80,000 (U/L), and edema with enhancement of the bilateral quadratus femoris muscles on pelvic MRI. Peroneus brevis muscle biopsy demonstrated severe myofiber atrophy, multifocal myofibrillar derangement and rare myonecrosis. There have been several cases of rhabdomyolysis complicating COVID-19 infection, including one as a presenting symptom [3], and the other as a later complication [4]. Neither of these cases had muscle biopsy performed. Of the four patients with brachial plexopathy, one had been managed with respiratory proning therapy while intubated and sedated who rapidly recovered indicating a compressive neurapraxic plexopathy caused by shoulder hyperabduction during proning, a well described complication of proning therapy in critically ill patients, before and after the advent of COVID-9 [5,6]. None of the remaining three patients with brachial plexopathies, one of whom underwent proning, nor the remaining three patients with bilateral sciatic neuropathies and the patient with upper extremity mononeuritis multiplex experienced any recovery during their hospitalization. MRI findings of these idiopathic brachial plexopathies and sciatic neuropathies are shown in Fig. 1.

#### 4. Discussion

Of the ten patients with entrapment neuropathies, one was found to have posterior interosseous nerve entrapment (PIN) at the arcade of Frohse in the supinator channel, which has not been described as a complication of prolonged immobilization due to sedation [7]. The patient underwent right posterior interosseous neurolysis with biopsy of the right medial antebrachial cutaneous nerve, due to clinical numbness in this nerve's territory with an absent right medial antebrachial cutaneous sensory response. The involvement of this nerve along with the posterior interosseous does suggest possible neuralgic amyotrophy or Parsonage Turner syndrome which has been described as a cause of posterior interosseous neuropathy [8]. There have been several cases of





**Nerve biopsy, MRI findings, and intraoperative photos:** (A) Epoxy resin section of the nerve, magnification x400. Axonal loss associated with numerous macrophages engulfing degenerating nerve fibers. (B) Electron microscopy, original magnification x5000. A macrophage appears to be stripping myelin sheath. (C) MRI FLAIR: normal intensity of the posterior interosseous branch of the radial nerve prior to the supinator tunnel, left, and increased intensity within the supinator tunnel, right. (D) MRI neurogram demonstrates enlargement and increased T2 hyperintensity of right sciatic nerve (white arrow). (E, F) MRI neurogram demonstrates increased T2 hyperintensity of right sciatic nerve (white arrow). (G) Intraoperative photos pre- (left) and post-surgical decompression (right) of the posterior interosseous branch of the radial nerve at the Arcade of Frohse. Abbreviations: FLAIR - fluid-attenuated inversion recovery

Parsonage Turner syndrome, including one that was pure sensory, associated with COVID-19 infection [9]. The medial antebrachial cutaneous biopsy was done to clarify the underlying neuropathology and etiology of this unusual neuropathy in this critically ill patient with COVID-19 infection. It revealed significant axonal loss and numerous phagocytosing macrophages present within the endoneurium. Electron microscopy showed remaining myelinated fibers were entirely or partially engulfed by macrophages, with some macrophages appearing to penetrate loosened myelin loops, occasionally exhibiting features of vesicular degeneration. Naked axons were also present in the widened and edematous endoneurium. Fig. 1 shows these nerve biopsy findings and intraoperative photographs of pre- and post-release of the posterior interosseous branch of the radial nerve at the Arcade of Frohse. We felt these biopsy findings were suggestive of microvascular thrombotic ischemia, however the findings were not robust.

We observed ten patients to have typical peripheral neurological complications of prolonged hospitalization [10], including entrapment neuropathies of the median, ulnar, radial and peroneal nerves. None of our patients had critical illness polyneuropathy or critical illness myopathy. Of note, five patients had systemic thrombotic complications, including deep venous thrombosis and pulmonary embolism. Two patients were diagnosed with COVID-19 cutaneous rashes, which have been suggested to be complement-mediated and caused by microscopic angiopathy from an underlying systemic process [11]. There was no clear correlation between the systemic thrombotic complications and a specific peripheral neurologic complication. No patient had premorbid plexopathy, peripheral neuropathy, or entrapment neuropathy to confound our observations.

Certain peripheral neurologic complications secondary to prolonged hospitalizations and ICU care are expected in patients with COVID-19, namely median, ulnar and peroneal entrapment neuropathies, critical illness polyneuropathy and critical illness myopathy [11]. The underlying cause may be lack of frequent position changes while hospitalized, such as prolonged extension of the knee for peroneal nerve injury and prolonged flexion of the elbow for cubital tunnel syndrome. These entrapment neuropathies are preventable and may be under-recognized. Preventative measures such as avoiding shoulder hyperabduction in prone patients, wedge pillows to maintain some knee flexion, extension bracing and padding at the elbows to prevent ulnar neurapraxias, with frequent physical therapy using passive range of motion, are crucial adjunctive therapies in COVID-19 patients to reduce the risk of developing peripheral neurological complications from prolonged hospitalization.

We also found patients with peripheral neurological complications that are not typical of prolonged hospitalization, specifically three cases of bilateral sciatic neuropathies, three patients with brachial plexopathies, and one ipsilateral median, musculocutaneous and radial mononeuritis multiplex patient. One possible mechanism for these findings may be the result of uncontrolled systemic inflammation triggering microthrombotic angiopathy involving the vasa nervorum. In support of this, we found complete clinical and electromyographic sparing of axillary and infraspinatus fascicles in two cases of otherwise severe brachial panplexopathies that showed complete clinical and electromyographic denervation of the musculocutaneous and radial fascicles in the upper trunks that anatomically carry these fascicles all together, suggesting a patchy microvascular injury to the epineural vasa nervorum supplying individual nerve fascicles of the upper brachial plexus trunks in these two patients. Coronaviruses such as severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) have previously been postulated to cause muscle and nerve injury through multiple mechanisms, including direct neuronal invasion, systemic inflammation and prolonged illness [12,13]. However, we did not find supporting pathological evidence for this on nerve biopsies, albeit from superficial peroneal nerves far distal from the injured sciatic nerves.

endothelial dysfunction have been proposed as the underlying mechanisms for COVID-19 neurological injury [1,2,13,14]. Viral entry into the central nervous system (CNS) via angiotensin-converting enzyme-2 (ACE2) receptors has been suggested to cause CNS pathologies such as ischemic strokes and encephalitis [14]. It is possible that SARS-CoV-2 may disrupt endothelial cell function in a similar ACE2 receptormediated mechanism involving the blood-nerve barrier, which could trigger the release of thrombogenic ultra-large von Willebrand factor (ULVWF) multimers and cause micro-thrombotic injury in the peripheral nerves. Under normal conditions, ULVWF multimers are cleaved by the protease ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) to prevent microthrombi formation [15]. COVID-19 patients have also been found to have moderately reduced serum level of ADAMTS-13, and subsequent excessive microthrombi in vasa nervorum could cause nerve ischemia and fascicular infarction in the setting of a refractory hypercoagulable state, not fully mitigated by current anti- inflammatory, anticoagulation, and antithrombotic therapies [15,16]. Alternative potential therapies could include monoclonal antibodies which inhibit complement activation, and plasmapheresis, which has been shown to reduce von Willebrand Factor concentration in plasma [16], potentially reducing the burden of micro-thrombotic injury in COVID-19.

Limitations of our observations include our small sample size and all male patient population. Furthermore, nerve biopsies could not be performed on the sciatic nerve or brachial plexus. Given the recent nature of the pandemic, we are likely only seeing glimpses of the long-term complications from COVID-19. Larger observational and longitudinal studies following the course and recovery of COVID-19 patients are crucial for better understanding of the underlying disease mechanisms.

#### 5. Conclusions

We present the main clinical and laboratory findings of patients with COVID-19 in our single institution who were found to have peripheral neurological complications. We further explore the possibility that these could be manifestations of the COVID-19 disease spectrum, hypothesizing that they could be related to micro-thrombotic induced nerve ischemia.

### **Financial disclosures**

None of the authors have conflicts of interest to disclose.

#### Study funding

No targeted funding reported.

#### **Publication history**

The manuscript is not under publication consideration elsewhere.

#### Ethical publication statement

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

#### Consents

Verbal informed consents were obtained from all patients at the initial clinical encounter. Institutional review board approval was obtained for this study.

#### Acknowledgements

Direct neuronal invasion, complement-mediated inflammation, and

We acknowledge Dr. Matthew Fink for his critical review.

#### Appendix A. Abbreviations

COVID-19	coronavirus disease 2019
AIDP	acute inflammatory demyelinating polyneuropathy
CRU	COVID-19 Recovery Unit
SARS-CoV-2	severe acute respiratory syndrome coronavirus-2
EDX	electrodiagnostic
CIM	critical illness myopathies
CIPN	critical illness polyneuropathy
MRI	magnetic resonance imaging
SARS	severe acute respiratory syndrome
MERS	Middle East respiratory syndrome
CNS	central nervous system
ACE2	angiotensin-converting enzyme-2
ULVWF	ultra-large von Willebrand factor
ADAMST13	a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13
CT	computerized tomography
L	left
R	right
m. biopsy	muscle biopsy
n. biopsy	nerve biopsy

#### References

- L. Mao, H. Jin, M. Wang, et al., Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China, JAMA Neurol. 77 (6) (2020) 683–690.
- [2] G. Toscano, F. Palmerini, S. Ravaglia, L. Ruiz, P. Invernizzi, M.G. Cuzzoni, D. Franciotta, F. Baldanti, R. Daturi, P. Postorino, A. Cavallini, G. Micieli, Guillain-Barré syndrome associated with SARS-CoV-2, N. Engl. J. Med. 382 (26) (2020 Jun 25) 2574–2576, https://doi.org/10.1056/NEJMc2009191. Epub 2020 Apr 17, 323 02082. PMC7182017.
- [3] K. Suwanwongse, N. Shabarek, Rhabdomyolysis as a presentation of 2019 novel coronavirus disease, Cureus 12 (4) (2020) e7561, https://doi.org/10.7759/ cureus.7561. Apr 6, 32382463. PMC7202588.
- [4] M. Jin, Q. Tong, Rhabdomyolysis as potential late complication associated with COVID-19, Emerg. Infect. Dis. 26 (7) (2020 Jul) 1618–1620, https://doi.org/ 10.3201/eid2607.200445. Epub 2020 Jun 21, 32197060. PMC7323559.
- [5] A. Sánchez-Soblechero, C.A. García, A. Sáez Ansotegui, J. Fernández-Lorente, I. Catalina-Álvarez, F. Grandas, J.L. Muñoz-Blanco, Upper trunk brachial plexopathy as a consequence of prone positioning due to SARS-CoV-2 acute respiratory distress syndrome, Muscle Nerve 62 (5) (2020 Nov) E76–E78, https:// doi.org/10.1002/mus.27055. Epub 2020 Sep 10, 32875575.
- [6] Joel O'Sullivan, Caroline Miller, Jack Jeffrey, Dominic Power, Brachial plexus neuropathies during the COVID-19 pandemic: a retrospective case series of 15 patients in critical care, Phys. Ther. 101 (1) (2021) 1–8, 2021-01-04, Vol.101 (1). Web.
- [7] Alan C. Dang, Craig M. Rodner, Unusual compression neuropathies of the forearm, part I: radial nerve, J. Hand Surg. (American Ed.) (2009) 1906–1914, 34.10.

- [8] Mao Akane, Katsuyuki Iwatsuki, Masahiro Tatebe, Takanobu Nishizuka, Shigeru Kurimoto, Michiro Yamamoto, Hitoshi Hirata, Anterior interosseous nerve and posterior interosseous nerve involvement in neuralgic amyotrophy, Clin. Neurol. Neurosurg. 151 (2016) 108–112.
- [9] Mario Cacciavillani, Alessandro Salvalaggio, Chiara Briani, Pure sensory neuralgic amyotrophy in COVID-19 infection, Muscle Nerve 63 (1) (2021) E7–E8.
- [10] C. Magro, J.J. Mulvey, D. Berlin, et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases, Transl. Res. J. Lab. Clin. Med. 220 (2020) 1–13.
- [11] Lisa D. Hobson-Webb, Vern C. Juel, Common entrapment neuropathies, CONTINUUM: Lifelong Learn. Neurol. 23 (2) (2017) 487–511.
- [12] L.-K. Tsai, S.-T. Hsieh, C.-C. Chao, et al., Neuromuscular disorders in severe acute respiratory syndrome, Arch. Neurol. 61 (11) (2004) 1669–1673.
- [13] Y.M. Arabi, A. Harthi, J. Hussein, et al., Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV), Infection 43 (4) (2015) 495–501.
- [14] A.M. Baig, A. Khaleeq, U. Ali, H. Syeda, Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms, ACS Chem. Neurosci. 11 (7) (2020) 995–998.
- [15] N. Morici, M. Bottiroli, R. Fumagalli, C. Marini, M. Cattaneo, Role of von Willebrand factor and ADAMTS-13 in the pathogenesis of thrombi in SARS-CoV-2 infection: time to rethink, Thromb. Haemost. (2020) 20–23.
- [16] U. Zachariah, S.C. Nair, A. Goel, et al., Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: consider low volume plasma exchange and low dose steroid, Thromb. Res. 192 (2020) 2.